You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: February 14, 2025

BAUSCH AND LOMB INC Company Profile


✉ Email this page to a colleague

« Back to Dashboard


Summary for BAUSCH AND LOMB INC
International Patents:379
US Patents:32
Tradenames:20
Ingredients:15
NDAs:20
Drug Master File Entries: 1

Drugs and US Patents for BAUSCH AND LOMB INC

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Bausch And Lomb Inc BROMDAY bromfenac sodium SOLUTION/DROPS;OPHTHALMIC 021664-002 Oct 16, 2010 DISCN Yes No ⤷  Try for Free ⤷  Try for Free
Bausch And Lomb Inc TIMOPTIC IN OCUDOSE timolol maleate SOLUTION/DROPS;OPHTHALMIC 019463-002 Nov 5, 1986 AT3 RX Yes Yes ⤷  Try for Free ⤷  Try for Free
Bausch And Lomb Inc MIEBO perfluorohexyloctane SOLUTION/DROPS;OPHTHALMIC 216675-001 May 18, 2023 RX Yes Yes 10,449,164 ⤷  Try for Free ⤷  Try for Free
Bausch And Lomb Inc XIBROM bromfenac sodium SOLUTION/DROPS;OPHTHALMIC 021664-001 Mar 24, 2005 DISCN Yes No ⤷  Try for Free ⤷  Try for Free
Bausch And Lomb Inc XIIDRA lifitegrast SOLUTION/DROPS;OPHTHALMIC 208073-001 Jul 11, 2016 RX Yes Yes 8,084,047 ⤷  Try for Free Y Y ⤷  Try for Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for BAUSCH AND LOMB INC

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Bausch And Lomb Inc MACUGEN pegaptanib sodium INJECTABLE;INTRAVITREAL 021756-001 Dec 17, 2004 6,011,020 ⤷  Try for Free
Bausch And Lomb Inc XIIDRA lifitegrast SOLUTION/DROPS;OPHTHALMIC 208073-001 Jul 11, 2016 7,745,460 ⤷  Try for Free
Bausch And Lomb Inc TIMOPTIC timolol maleate SOLUTION/DROPS;OPHTHALMIC 018086-002 Approved Prior to Jan 1, 1982 4,195,085 ⤷  Try for Free
Bausch And Lomb Inc TIMOPTIC-XE timolol maleate SOLUTION, GEL FORMING/DROPS;OPHTHALMIC 020330-002 Nov 4, 1993 4,861,760 ⤷  Try for Free
Bausch And Lomb Inc TIMOPTIC-XE timolol maleate SOLUTION, GEL FORMING/DROPS;OPHTHALMIC 020330-002 Nov 4, 1993 4,195,085 ⤷  Try for Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration
Paragraph IV (Patent) Challenges for BAUSCH AND LOMB INC drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Ophthalmic Solution 1.5% ➤ Subscribe 2013-09-09

Supplementary Protection Certificates for BAUSCH AND LOMB INC Drugs

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0799044 02C0040 France ⤷  Try for Free PRODUCT NAME: OLOPATADINE HYDROCHLORIDE; REGISTRATION NO/DATE: EU/1/02/217/001 20020517
2826776 301105 Netherlands ⤷  Try for Free PRODUCT NAME: EEN COMBINATIE VAN (A) (R)-1-(2,2-DIFLUOROBENZO(D)(1,3)DIOXOL-5-YL)-N-(1-(2,3-DIHYDROXYPROPYL)-6-FLUOR-2-(1-HYDROXY-2-METHYLPROPAN-2-YL)-1H-INDOL-5-YL)CYCLOPROPAANCARBOXAMIDE OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN EN (B) N-(5-HYDROXY-2,4-DITERT-BUTYL-FENYL)-4-OXO-1H-CHINOLINE-3-CARBOXAMIDE OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN; REGISTRATION NO/DATE: EU/1/18/1306 20181106
0957929 SPC/GB06/021 United Kingdom ⤷  Try for Free PRODUCT NAME: PEGAPTANIB, PREFERABLY IN THE FORM OF ITS SODIUM SALT; REGISTERED: UK EU/1/05/325/001 20060201
2826776 122021000025 Germany ⤷  Try for Free PRODUCT NAME: EINE KOMBINATION VON (A) (R)-1-(2,2-DIFLUORBENZO(D)(1,3)DIOXOL-5-YL)-N-(1-(2,3-DIHYDROXYPROPYL)-6-FLUOR-2-(1-HYDROXY-2-METHYLPROPAN-2-YL)-1H-INDOL-5-YL)CYCLOPROPANCARBOXAMID ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON UND (B) N-(5-HYDROXY-2,4-DI-TERT-BUTYL-PHENYL)-4-OXO-1H-CHINOLIN-3-CARBOXAMID ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON; REGISTRATION NO/DATE: EU/1/18/1306 20181031
1586316 11C0031 France ⤷  Try for Free PRODUCT NAME: BROMFENAC, SES SELS OU HYDRATES PHARMACOLOGIQUEMENT ACCEPTABLES; REGISTRATION NO/DATE: EU/1/11/692/001 20110518
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

BAUSCH AND LOMB INC Market Analysis and Financial Projection

Pharmaceutical Competitive Landscape Analysis: Bausch And Lomb Inc – Market Position, Strengths & Strategic Insights

In the ever-evolving pharmaceutical industry, Bausch and Lomb Inc. stands as a prominent player, particularly in the eye care sector. Let's dive into an in-depth analysis of the company's market position, strengths, and strategic insights to understand how it navigates the competitive landscape.

The Eye Care Giant: An Overview

Bausch and Lomb Inc., with its rich history dating back to 1853, has established itself as a global leader in eye health products. The company's diverse portfolio spans across vision care, pharmaceuticals, and surgical equipment, positioning it as a one-stop solution for ophthalmology needs[6].

Market Position: A Force to Reckon With

Bausch and Lomb's market position is nothing short of impressive. The company's strong presence in over 100 countries speaks volumes about its global reach and market penetration[6]. This extensive geographical footprint not only insulates the company from demand fluctuations in individual markets but also provides a solid foundation for sustained growth.

Dominating the Eye Care Segment

In the eye care segment, Bausch and Lomb has carved out a significant market share. The company's fully integrated eye-health business gives it a competitive edge, contributing to a substantial portion of its total revenue. In fact, the eye-health business accounted for 41-43% of the company's total revenue from 2017 to 2019[2].

"Bausch+Lomb's 165 year legacy and the fully integrated nature of the eye-health business helps it maintain a competitive edge over competition and create value for the parent company." - SWOT and PESTLE Analysis[2]

Strengths: The Pillars of Success

Bausch and Lomb's success in the pharmaceutical landscape can be attributed to several key strengths:

1. Diverse Product Portfolio

One of Bausch and Lomb's most significant strengths lies in its diverse product offerings. The company develops and markets a wide array of eye care products, including contact lenses, lens care solutions, pharmaceuticals, and surgical instruments[3]. This extensive range allows Bausch and Lomb to cater to various eye conditions and consumer needs, enhancing its appeal across different market segments.

2. Strong Global Presence

With operations spanning more than 100 countries, Bausch and Lomb's global presence is a formidable strength[6]. This geographical diversity not only reduces exposure to localized market risks but also enables the company to tap into emerging markets for future growth.

3. Robust Research and Development

Bausch and Lomb's commitment to innovation is evident in its focus on research and development. The company's pipeline boasts 225 products, showcasing its dedication to bringing novel treatments to market[2]. This emphasis on R&D positions Bausch and Lomb at the forefront of technological advancements in the eye care industry.

4. Brand Equity

The Bausch and Lomb brand carries significant weight in the eye care industry. Products like Lumify, which dominates the redness reliever category with a 50% market share, exemplify the company's strong brand equity[1]. This brand strength not only drives customer loyalty but also facilitates successful product launches in new geographies.

Strategic Insights: Navigating the Competitive Landscape

To maintain its competitive edge, Bausch and Lomb employs several strategic initiatives:

1. Focus on Innovation

Innovation remains at the heart of Bausch and Lomb's strategy. The company continually invests in developing cutting-edge products to address unmet medical needs. For instance, the recent approval of MIEBO™ for dry eye disease treatment showcases the company's commitment to bringing innovative solutions to market[9].

2. Strategic Acquisitions

Bausch and Lomb actively pursues strategic acquisitions to expand its product portfolio and market reach. The recent acquisition of Blink, an eye and contact lens drop brand, from Johnson & Johnson for $106.5 million exemplifies this strategy[1]. While the immediate revenue impact may be modest, such acquisitions strengthen the company's market position and product offerings.

3. Expansion into Emerging Markets

Recognizing the growth potential in emerging markets, Bausch and Lomb is actively expanding its presence in these regions. The company's strong performance in China, with a 24% growth on constant currency, underscores the success of this strategy[1].

4. Leveraging Telehealth

In response to changing healthcare dynamics, Bausch and Lomb is exploring opportunities in telehealth. By integrating telehealth solutions into its fully integrated eye-health business, the company aims to enhance accessibility and convenience for consumers[2].

Competitive Landscape: Challenges and Opportunities

While Bausch and Lomb enjoys a strong market position, it operates in a highly competitive landscape. Major players like Johnson & Johnson, Alcon, and CooperVision pose significant competition[10]. Additionally, the company faces challenges such as:

1. Supply Chain Disruptions

Global supply chain challenges persist, potentially leading to delays in product availability and increased costs related to logistics and raw materials[10].

2. Regulatory Environment

As a pharmaceutical company, Bausch and Lomb is subject to stringent regulatory oversight. Changes in healthcare regulations or approval processes can impact product launches and operational costs[10].

3. Currency Fluctuations

Given its global operations, Bausch and Lomb is exposed to risks from currency fluctuations, which can affect profitability from foreign markets[10].

Future Outlook: Poised for Growth

Despite these challenges, Bausch and Lomb's future outlook appears promising. The global eye care market is projected to expand at a compound annual growth rate (CAGR) of 4.4% from 2022 to 2030, presenting significant growth opportunities[10].

Analysts project Bausch and Lomb's revenue to grow by approximately 6% per year through 2025, with earnings before interest, taxes, depreciation, and amortization (EBITDA) expected to reach around $1.2 billion by 2025[10].

Key Takeaways

  1. Bausch and Lomb holds a strong market position in the eye care industry, with a diverse product portfolio and global presence.
  2. The company's strengths lie in its brand equity, robust R&D, and fully integrated eye-health business.
  3. Strategic initiatives focus on innovation, acquisitions, emerging market expansion, and leveraging telehealth.
  4. While facing competition and challenges like supply chain disruptions, Bausch and Lomb is well-positioned for future growth in the expanding eye care market.
  5. Analysts project steady revenue growth for the company, reflecting its strong market position and strategic initiatives.

FAQs

  1. What is Bausch and Lomb's primary focus in the pharmaceutical industry? Bausch and Lomb primarily focuses on eye health products, including vision care, pharmaceuticals, and surgical equipment.

  2. How does Bausch and Lomb maintain its competitive edge? The company maintains its competitive edge through a diverse product portfolio, strong global presence, robust R&D, and strategic acquisitions.

  3. What are some of Bausch and Lomb's most successful products? Some of Bausch and Lomb's successful products include Lumify, which dominates the redness reliever category, and their daily silicone hydrogel contact lenses.

  4. How is Bausch and Lomb adapting to the changing healthcare landscape? Bausch and Lomb is exploring opportunities in telehealth and focusing on innovation to adapt to changing healthcare dynamics.

  5. What are the main challenges facing Bausch and Lomb in the competitive landscape? The main challenges include intense competition from other major players, supply chain disruptions, regulatory changes, and currency fluctuations due to global operations.

Sources cited: [1] https://www.morningstar.com/stocks/bausch-lomb-earnings-gains-eye-care-pharma-record-strong-sales-offset-supply-issues [2] https://www.swotandpestle.com/bausch-health/ [3] https://www.latterly.org/bausch-lomb-swot-analysis/ [6] https://www.marketing91.com/swot-analysis-bausch-lomb/ [9] https://ir.bausch.com/press-releases/bausch-lomb-announces-second-quarter-2023-results-and-raises-full-year-2023-revenue [10] https://dcfmodeling.com/blogs/health/blco-financial-health

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.